ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago. These figures are ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...

ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a ...

ImmunityBio, Inc.’s IBRX share price has surged by 10.14%, which has investors questioning if this is right time to sell.

Shares of ImmunityBio Inc. grew as much as 18.8 percent at intraday trading before ending the day just up by 14.01 percent at ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...

In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other low risk high reward stocks set to triple by 2030. The market is getting tough these days ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $129.6 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of 15 ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $129.6 million in its first quarter. On a per-share basis, the San Diego-based company said it had a ...